Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction chemotherapy and for patients who have relapsed/refractory (R/R) acute myeloid leukemia (AML). This study retrospectively analyzed the outcomes of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Hemasphere
Autores principales: Feld, Jonathan, Tremblay, Douglas, Dougherty, Mikaela, Czaplinska, Tina, Sanchez, Gillian, Brady, Claudia, Kremyanskaya, Marina, Bar-Natan, Michal, Keyzner, Alla, Marcellino, Bridget K., Gabrilove, Janice, Navada, Shyamala C., Silverman, Lewis R., El Jamal, Siraj M., Mascarenhas, John, Shih, Alan H.
Formato: Artigo
Lenguaje:Inglês
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7951133/
https://ncbi.nlm.nih.gov/pubmed/33718803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000549
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares